Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests.
Zacks Investment Research on MSN
Quest Diagnostics Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
Quest Diagnostics Inc.’s DGX third-quarter 2025 adjusted earnings per share (EPS) of $2.60 beat the Zacks Consensus Estimate by 3.59%. The metric also exceeded the year-ago adjusted figure by 13%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback